Table 1.

Oligonucleotides used in this study.

ID	Sequence (5′ to 3′)
CtrASO (a) (apoB-targeting cholesterol-lowering positive control)	HºHºHºG^C^a^t^t^g^g^t^a^t^T^C^A
tinyLNA	C^A^C^A^C^T^C^C
tL-5G3	HºHºHºC^A^C^A^C^T^C^C
tinyCtr-5G3 (b)	HºHºHºT^C^A^T^A^C^T^A
tL-5G1	HºC^A^C^A^C^T^C^C
tL-5G3-PO	HºHºHºCºAºCºAºCºTºCºC
tL-5G3-PS	H^H^H^C^A^C^A^C^T^C^C
tL-3G3	C^A^C^A^C^T^C^CºHºHºH
Anti-miR122-probe	5′-FºaºcºAºaºaºCºaºcºCºaºtºTºgºtº CºaºcºAºcºtºCºcºaºF-3′
tinyLNA-f (b)	C^A^C^A^C^T^C^C^f
tL-5G3-f (b)	HºHºHºC^A^C^A^C^T^C^C^f

Upper and lower case letters indicate 2′,4′-BNA/LNA and native DNA, respectively. H represents monovalent GalNAc. ^ and º indicate a phosphorothioate (PS) linkage and phosphodiester (PO) linkage, respectively. F and f denote the FAM and Alexa Fluor^TM 647 fluorophores, respectively. ^(a) A GalNAc-conjugated apolipoprotein-B targeting ASO that we have previously reported as a highly potent ASO [18], which was used here as a potent cholesterol-lowering positive control. All oligonucleotides were synthesized by Gene Design Inc., except for those labeled as ^(b).